{"filing":{"accession_number":"0001829126-26-007767","cik":"0002079364","ticker":null,"company_name":"Veraxa Biotech AG","form":"6-K","filing_date":"2026-07-23","report_date":null,"primary_document":"veraxabiotechag_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079364/000182912626007767/veraxabiotechag_6k.htm"},"events":[{"id":19814,"run_id":17830,"accession_number":"0001829126-26-007767","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The press release announces the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO) of VERAXA Biotech AG, effective immediately. This is a named executive officer appointment to a C-suite role responsible for directing development of the company's proprietary BiTAC® platform technologies. The disclosure also notes the departure of the prior CSO, Rick Austin, Ph.D., but the principal disclosed action is Erkel's appointment to the CSO position.","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-23","form":"6-K","submitted_at":null,"items":[{"id":19009,"accession_number":"0001829126-26-007767","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO) of VERAXA Biotech AG, effective immediately. This is a named executive officer appointment to a C-suite role responsible for directing development of the company's proprietary BiTAC® platform technologies. The disclosure also notes the departure of the prior CSO, Rick Austin, Ph.D., but the principal disclosed action is Erkel's appointment to the CSO position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:17:38.288536+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19009,"accession_number":"0001829126-26-007767","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO) of VERAXA Biotech AG, effective immediately. This is a named executive officer appointment to a C-suite role responsible for directing development of the company's proprietary BiTAC® platform technologies. The disclosure also notes the departure of the prior CSO, Rick Austin, Ph.D., but the principal disclosed action is Erkel's appointment to the CSO position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:17:38.288536+00:00","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-23"}]}